Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease.

MacDonald, Kelli P A; Betts, Brian C; Couriel, Daniel

MacDonald, Kelli P A; Betts, Brian C; Couriel, Daniel.

Affiliation

MacDonald KPA; Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Electronic address: Kelli.MacDonald@qimrberghofer.edu.au.
Betts BC; Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffit Cancer Center, Tampa, Florida.
Couriel D; Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah.

Biol Blood Marrow Transplant ; 24(1): 19-26, 2018 01.

Article in En | MEDLINE | ID: mdl-29032060

Subject(s)

Graft vs Host Disease/prevention & control; Therapeutics/trends; Chronic Disease; Hematopoietic Stem Cell Transplantation/adverse effects; Humans; Interleukin-17/immunology; Janus Kinase Inhibitors/immunology; Transplantation, Homologous/adverse effects

Key words

Allogeneic hematopoietic cell transplantation; Chronic GVHD; Graft-versus-host disease; Interleukin-17A; JAK inhibitor

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Therapeutics / Graft vs Host Disease Limits: Humans Language: En Journal: Biol Blood Marrow Transplant Journal subject: HEMATOLOGIA / TRANSPLANTE Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google